Literature DB >> 15148836

Markers of inflammation and oxidative stress during lower respiratory tract infections in COPD patients.

W J van Beurden1, F W Smeenk, G A Harff, P N Dekhuijzen.   

Abstract

BACKGROUND: Lower respiratory tract infections (LRTI) occur frequently in patients with Chronic Obstructive Pulmonary Disease (COPD), and are a major cause of morbidity, mortality and health care utilization. The aim of this study was to investigate if non- or less invasive markers of inflammation and oxidative stress can predict the course of the infections.
METHODS: Twenty-five COPD patients who were admitted to hospital with a LRTI were included. Within 24 hours after admittance, spirometry (FEV1, FVC, MEF50), measurement of hydrogen peroxide (H2O2) in exhaled breath condensate (EBC), symptom scores and analyses of ESR, CRP, ECP, and MPO in serum were performed. All patients were treated with intravenous dexamethasone, nebulised salbutamol/ipratropium and, if needed, antibiotics. The tests were repeated at day 2, 3, 7 and 30.
RESULTS: Complete data of the first four visits were collected in 19 patients. The H2O2 concentration and spirometry parameters did not change significantly during the study period. CRP, ESR and MPO levels decreased significantly during treatment, while the other serum inflammatory parameters did not change. There were no significant correlations between H2O2 concentration, spirometry and serum inflammatory parameters.
CONCLUSIONS: In conclusion, this study showed no significant changes in H2O2 concentration in EBC, or spirometry during treatment of a LRTI in COPD patients. In contrast, several serum inflammatory markers did decrease during hospitalization, thus providing a simple tool to monitor exacerbations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15148836

Source DB:  PubMed          Journal:  Monaldi Arch Chest Dis        ISSN: 1122-0643


  4 in total

Review 1.  COPD exacerbations . 2: aetiology.

Authors:  E Sapey; R A Stockley
Journal:  Thorax       Date:  2006-03       Impact factor: 9.139

2.  Non-invasive evaluation of pulmonary glutathione in the exhaled breath condensate of otherwise healthy alcoholics.

Authors:  Mary Y Yeh; Ellen L Burnham; Marc Moss; Lou Ann S Brown
Journal:  Respir Med       Date:  2007-10-30       Impact factor: 3.415

3.  High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease.

Authors:  R Zuin; A Palamidese; R Negrin; L Catozzo; A Scarda; M Balbinot
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 4.  Experimental rhinovirus infection in COPD: implications for antiviral therapies.

Authors:  Natasha Gunawardana; Lydia Finney; Sebastian L Johnston; Patrick Mallia
Journal:  Antiviral Res       Date:  2013-12-24       Impact factor: 5.970

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.